Zhejiang East Asia Pharmaceutical Co., Ltd.

SHSE:605177 Stock Report

Market Cap: CN¥2.0b

Zhejiang East Asia Pharmaceutical Past Earnings Performance

Past criteria checks 1/6

Zhejiang East Asia Pharmaceutical's earnings have been declining at an average annual rate of -5.1%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 13.2% per year. Zhejiang East Asia Pharmaceutical's return on equity is 4%, and it has net margins of 6.1%.

Key information

-5.1%

Earnings growth rate

-13.9%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate13.2%
Return on equity4.0%
Net Margin6.1%
Next Earnings Update30 Apr 2025

Recent past performance updates

Zhejiang East Asia Pharmaceutical's (SHSE:605177) Shareholders Have More To Worry About Than Only Soft Earnings

Nov 06
Zhejiang East Asia Pharmaceutical's (SHSE:605177) Shareholders Have More To Worry About Than Only Soft Earnings

Zhejiang East Asia Pharmaceutical's (SHSE:605177) Solid Profits Have Weak Fundamentals

May 06
Zhejiang East Asia Pharmaceutical's (SHSE:605177) Solid Profits Have Weak Fundamentals

Recent updates

Zhejiang East Asia Pharmaceutical's (SHSE:605177) Shareholders Have More To Worry About Than Only Soft Earnings

Nov 06
Zhejiang East Asia Pharmaceutical's (SHSE:605177) Shareholders Have More To Worry About Than Only Soft Earnings

Zhejiang East Asia Pharmaceutical Co., Ltd.'s (SHSE:605177) Shares Lagging The Market But So Is The Business

Oct 02
Zhejiang East Asia Pharmaceutical Co., Ltd.'s (SHSE:605177) Shares Lagging The Market But So Is The Business

Zhejiang East Asia Pharmaceutical's (SHSE:605177) Solid Profits Have Weak Fundamentals

May 06
Zhejiang East Asia Pharmaceutical's (SHSE:605177) Solid Profits Have Weak Fundamentals

Zhejiang East Asia Pharmaceutical Co., Ltd. (SHSE:605177) Stock Catapults 26% Though Its Price And Business Still Lag The Market

Apr 23
Zhejiang East Asia Pharmaceutical Co., Ltd. (SHSE:605177) Stock Catapults 26% Though Its Price And Business Still Lag The Market

Take Care Before Diving Into The Deep End On Zhejiang East Asia Pharmaceutical Co., Ltd. (SHSE:605177)

Feb 28
Take Care Before Diving Into The Deep End On Zhejiang East Asia Pharmaceutical Co., Ltd. (SHSE:605177)

Revenue & Expenses Breakdown

How Zhejiang East Asia Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SHSE:605177 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241,3158117795
30 Jun 241,3309916595
31 Mar 241,33912215887
31 Dec 231,35612115082
30 Sep 231,33012913668
30 Jun 231,31811713556
31 Mar 231,29410513351
31 Dec 221,18010412445
30 Sep 221,0947613141
30 Jun 229025212438
31 Mar 227786611836
31 Dec 217126811537
30 Sep 216776011835
30 Jun 217208711537
31 Mar 2192613212341
31 Dec 2088211412838
30 Sep 2094114612539
31 Dec 1998816811037
31 Dec 188571099433
31 Dec 17729569031
31 Dec 16684678227

Quality Earnings: 605177 has high quality earnings.

Growing Profit Margin: 605177's current net profit margins (6.1%) are lower than last year (9.7%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 605177's earnings have declined by 5.1% per year over the past 5 years.

Accelerating Growth: 605177's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 605177 had negative earnings growth (-37.3%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.5%).


Return on Equity

High ROE: 605177's Return on Equity (4%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/07 19:24
End of Day Share Price 2025/02/07 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Zhejiang East Asia Pharmaceutical Co., Ltd. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Xiao Wei LinEverbright Securities Co. Ltd.
Mingrui WangEverbright Securities Co. Ltd.